OLPRUVA™ preliminary launch activities progressing; building out commercial and medical affairs teams to support U.S. launch in Q2 2023, with drug availability anticipated by early July 2023 Poster ...

Zevra Therapeutics has partnered with the National Urea Cycle Disorders Foundation (NUCDF) to run an awareness campaign designed to improve the diagnosis of conditions treated by one of its products.

The European Commission (EC) granted orphan designation to iECURE's lead product GTP-506 to treat Ornithine Transcarbamylase (OTC) deficiency. OTC deficiency is a type of urea cycle disorder. It is a ...

INDIANAPOLIS — An Indiana University School of Medicine physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the ...

The application was approved through the FDA’s 505(b)(2) regulatory pathway. The Food and Drug Administration (FDA) has approved Olpruva ™ (sodium phenylbutyrate) as an oral suspension for the ...

An Indiana University School of Medicine physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States. By ...

An Indiana University School of Medicine physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States. By ...

A physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States. An Indiana University School of Medicine ...

Arginase deficiency is a rare autosomal recessive metabolic disorder that disrupts the final step of the urea cycle, impairing the conversion of arginine into urea and ornithine. In affected ...

(Reuters) - U.S. health regulators on Friday approved a drug from Hyperion Therapeutics Inc designed to remove ammonia buildup from the blood of patients with enzyme deficiencies known as urea cycle ...